Browsing Publikasjoner fra Cristin - St. Olavs hospital by Author "Werlenius, Katja"
Now showing items 1-2 of 2
-
Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells
Wenger, Anna; Werlenius, Katja; Hallner, Alexander; Fredrik Bergh, Thoren; Farahmand, Dan; Tisell, Magnus; Smits, Anja; Rydenhag, Bertil; Jakola, Asgeir Store; Caren, Helena (Peer reviewed; Journal article, 2018)Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of less than 15 months, emphasizing the need for better treatments. Immunotherapy as a treatment for improving or aiding the patient’s ... -
Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients with Recurrent Glioblastoma: A Randomized Clinical Trial
Werlenius, Katja; Kinhult, Sara; Solheim, Tora S; Magelssen, Henriette; Löfgren, David; Mudaisi, Munila; Hylin, Sofia; Bartek, Jiri; Strandéus, Michael; Lindskog, Magnus; Rashid, Havyan Bahroz; Carstam, Louise; Gulati, Sasha; Solheim, Ole Skeidsvoll; Salvesen, Øyvind Olav; Jakola, Asgeir Store (Peer reviewed; Journal article, 2023)Importance Disulfiram has demonstrated broad antitumoral effect in several preclinical studies. One of the proposed indications is for the treatment of glioblastoma. Objective To evaluate the efficacy and safety of ...